Home›Trial›NCT06040541
🔬NCT06040541Phase 1RECRUITING

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Study Summary

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Conditions
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors
Interventions / Drugs
RMC-9805RMC-6236
View on ClinicalTrials.gov ↗
Sponsor
RVMD
Revolution Medicines
Precision Oncology
F35/100
Study Details
Enrollment604 participants
Primary Completion—
Lead SponsorRevolution Medicines, Inc.
Data Retrieved2026-04-11 04:26:28.070702+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.